Yarrow Bioscience Posts $9.7M Q3 Loss, $268.9M Cash to 2030

Yarrow Bioscience, Inc. (Nasdaq: YARW) reported a net loss of $9.7 million for the third quarter ended September 30, 2026, alongside cash and cash equivalents of $268.9 million, the clinical-stage biotech said on November 12, 2026. The company completed a roughly $172.5 million underwritten public offering in September 2026 and said that balance should fund operations into 2030. Yarrow is developing YB-101, an anti-TSHR antibody, in Graves' disease and thyroid eye disease, with Phase 2a topline data expected in the second half of 2027.

Context — why the cash runway matters more than the loss

Yarrow's third quarter is best read against its own prior-year balance sheet, which the company disclosed in the same report. At December 31, 2025, Yarrow held $99,994 thousand in cash and cash equivalents and carried an accumulated deficit of $70,994 thousand. By September 30, 2026, cash had risen to $268,860 thousand and the accumulated deficit had widened to $89,975 thousand.

The swing is not operational. It follows the July 2026 completion of Yarrow's merger with VYNE Therapeutics Inc., after which the combined company began trading on the Nasdaq Capital Market under the ticker "YARW," and the September 2026 offering of 6,634,615 shares, including full exercise of the underwriters' option.

The merger also cleared the capital structure. Convertible preferred stock fell from 14,516,188 shares issued and outstanding at December 31, 2025, carrying a $100,000 thousand liquidation value, to zero at September 30, 2026. Additional paid-in capital moved from $4 thousand to $357,492 thousand over the same span.

For a clinical-stage company with no product revenue, the runway is the valuation anchor. Yarrow said the cash funds operations into 2030, including completion of the DIRECTION-GD trial and preparatory work for its next planned thyroid eye disease study.

Data — what the numbers show

The income statement is small relative to the balance sheet. Research and development expenses were $5,277 thousand for the quarter and $11,461 thousand for the nine months ended September 30, 2026. General and administrative expenses were $5,466 thousand for the quarter and $8,839 thousand for the nine months. Total operating expenses reached $10,743 thousand in the quarter and $20,300 thousand across nine months.

Interest and other income of $1,019 thousand in the quarter partly offset that spend, leaving the $9,724 thousand net loss. Loss per share was $0.43 basic and diluted for the quarter and $1.97 for the nine months, on weighted average shares of 22,593 thousand and 9,635 thousand respectively.

Metric	Q3 2026	Nine months 2026
R&D expense	$5,277K	$11,461K
G&A expense	$5,466K	$8,839K
Net loss	$9,724K	$18,981K
Loss per share	$0.43	$1.97

Total assets stood at $274,029 thousand against total liabilities of $6,511 thousand. The company reported approximately 11.5 million shares of common stock issued and outstanding at September 30, 2026, plus pre-funded warrants to purchase approximately 23.7 million additional shares. Yarrow did not disclose the exercise price or terms of those pre-funded warrants in the report.

Analysis — what it means for biotech and thyroid disease

Yarrow's balance sheet now dwarfs its burn. Quarterly operating expenses of $10,743 thousand against $268.9 million in cash imply a multi-year funding horizon at current spend, and the company explicitly ties that horizon to finishing DIRECTION-GD and preparing a thyroid eye disease study.

The trial design is the second signal. DIRECTION-GD is a Phase 2a/2b randomized, blinded, placebo-controlled trial in Graves' disease patients, with or without concomitant thyroid eye disease. The Phase 2a portion aims to enroll 32 patients across four cohorts and measures safety, pharmacokinetics, pharmacodynamics and efficacy through 24 weeks, including the share of patients who are euthyroid and off anti-thyroid drugs. The Phase 2b portion is expected to enroll approximately 200 patients starting in the first half of 2028.

The counter-argument is timing. Phase 2a topline data are not expected until the second half of 2027, and Phase 2b dosing is to be set only after that readout. A negative or ambiguous Phase 2a result would leave the Phase 2b design unresolved and the thyroid eye disease program dependent on partner data. Yarrow noted that licensing partner Changchun GeneScience Pharmaceutical Co., Ltd. is running a Phase 1 multiple ascending dose trial in thyroid eye disease, with data also anticipated in the second half of 2027.

Positioning follows that calendar. Clinical-stage biotech with a fully funded runway and a binary readout more than a year out tends to attract event-driven holders rather than momentum flow, and the pre-funded warrants overhang the share count.

Outlook — what to watch next

The next hard catalysts are enrollment progress in the Phase 2a portion of DIRECTION-GD and the second-half 2027 readouts. Yarrow said Phase 2a topline results are expected in the second half of 2027, and that GenSci's Phase 1 multiple ascending dose data in thyroid eye disease are anticipated in the same window. The Phase 2b portion is expected to begin enrolling in the first half of 2028.

On the regulatory side, YB-101 holds Fast Track Designation from the U.S. Food and Drug Administration, which the company said is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical needs.

The report gives no price levels, moving averages or analyst targets for YARW, so there are no technical thresholds to track. The measurable items are cash burn against the stated 2030 runway, share count including the pre-funded warrants, and the timing of the Phase 2a readout. Any slip in that readout window would compress the runway narrative that underpins the equity story.

Frequently Asked Questions

What does Yarrow Bioscience's Q3 2026 loss mean for retail investors?

It means the company is spending, not earning, and its value rests on trial outcomes. Yarrow reported a $9.7 million quarterly net loss against $268.9 million in cash, which it says funds operations into 2030. There is no product revenue in the report. For holders, the relevant variables are trial timing and cash burn, not quarterly profit.

What happens next for Yarrow Bioscience and YB-101?

Enrollment continues in the Phase 2a portion of DIRECTION-GD, with topline results expected in the second half of 2027. The Phase 2b portion, a roughly 200-patient dose-finding trial, is expected to start enrolling in the first half of 2028. Partner GenSci's Phase 1 multiple ascending dose data in thyroid eye disease are also expected in the second half of 2027.

Why did Yarrow's cash and share count change so much?

Two corporate events drove it. Yarrow completed its merger with VYNE Therapeutics in July 2026 and began trading as YARW, then raised roughly $172.5 million in a September 2026 offering of 6,634,615 shares. Cash rose from $99,994 thousand at December 31, 2025, to $268,860 thousand at September 30, 2026, while convertible preferred stock fell to zero.

Bottom Line

Yarrow's $268.9 million cash pile buys time to 2030, but the equity story now hinges entirely on a Phase 2a readout due in the second half of 2027.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.